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Abstract The activity of a cysteine proteinase purified from Staphylococcus aureus V8 (SAVI) was inhibited by phosphorylated cystatin a (Pqstatin 
a) and by purified corn&d envelope protein of newborn rat, a conjugated form of P-cyst&in a. Immunohistochemical nalysis demonstrated a
marked decrease in P-cystatin a content in conrifled envelope treated with sphingosine. The inhibition of papain activity by proteins from 
sphingosine-treated skin was much weaker than that exerted by proteins from the untreated skin. The suppression of SAVI colony formation 
inoculated on the sphingosin~treated skin was examined. Colony formation on the sphingosine-treated skin was enhanced compared to that on 
normal skin. These findings suggest hat P-cystatin a in the corn&d envelope may have a bacteriostatic barrier function against bacterial infection, 
such as that with SAVS. 
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1. Introduction 
Cystatin a is specifically located only in the epidermis [ 11. In 
our previous studies, we reported that cystatin a was 
phosphorylated by protein kinase C [2] and that 
phosphorylated cyst&in a (P-cyst&in a) was incorporated in 
the keratohyalin granules of the stratum granulosurn [3]. P- 
cystatin a is conjugated with other glutamine-rich skin protein 
components, such as filaggrin, in the cornified envelope [4]. 
These findings suggested that P-cystatin a in the comified enve- 
lope would have an inhibitory effect against bacterial and viral 
cysteine proteinases. Korant et al. [5,6] reported that egg white 
cystatin inhibited the cysteine proteinase of the picoma virus 
and inhibited the processing of the virus precursor protein. It 
was found that the replication of Herpes simplex was blocked 
by cystatin C [7]. In this study, we found that P-cystatin a in 
the comified envelope appeared to inhibit bacterial and viral 
cysteine proteinases, suggesting that skin P-cystatin a may play 
a role as a protective barrier against bacterial and viral i&c- 
tions. 
2. Materials and methods 
2.1. Materials 
Newborn SpraguoDawley rats were purchased from SLC, Japan. 
Stauhvlococcus aureus V8 was obtained from ATCC, USA. Sunerdex 
7S,*Superose 12, and Mono Q columns were purchased from Pharma- 
cia-LKB, Sweden. Papain and sphingosine were obtained from Sigma, 
USA. Aminomethyl-coumarin (MCA) substrate was purchased from 
the Peptide Institute, Japan. Food stamp ‘Nissui’ for the specific detec- 
tion of SAVS colonies on the skin was obtained from Nissui Pharma- 
ceutical Co., Ltd., Japan. 
*Corresponding author. 
Abbreviations: P-cystatin a, phosphorylated cystatin a; PoAb, polyclo- 
nal antibody; SAV8, Staphylococcus aureus V8. 
2.2. Purification of P-cystatin a andpreparation ofpolyclonal antibody 
for P-cystatin a 
P-cystatin a was purified to homogeneity by 2dimensional electro- 
phoresis, as described previously [8]. Three-day-old rat epidermal ex- 
tract in 50 mM Tris-HCl (PH 7.4) was ubjected to preparative isoelec- 
tric focusing, to Superose 12 gel filtration and finally to Mono Q 
anion-exchange column chromatography. The purified P-cystatin a 
was then injected to rabbits to prepare the polyclonal antibody (PoAb). 
2.3. Preparation of cornt@ed envelope from newborn rat stratum 
corneum 
The comified envelope was prepared from newborn rat stratum cor- 
neum with 8 M urea in 50 mM Tris-HCl (pH 9.0), containing 10 mM 
2-mercaptoethanol, at 95’C for 10 min and sonicated. After centrifuga- 
tion, the residue was washed 3 times with 50 mM Tris-HCl (PH 7.5) and 
then 3 times with distilled water, after which it was freeze-dried. To 
prepare a sample for immunoelectron microscopy, the stratum cor- 
neum was treated with 1% SDS at 95‘C for 10 min and sonicated. The 
sample was then washed with 50 mM Tris-HCl buffer (PH 7.5) contain- 
ing 1% Triton X-100. 
2.4. Partial purification of SAV8 cysteine proteinase 
SAVS was cultured in Staphylococcus aureus medium No. 110 for 8 h 
at 37°C [9]. The culture medium with the cells was sonicated, filtered, 
and concentrated. Cysteine proteinase activity was determined with 
Z-Phe-Arg-MCA as a substrate in the presence of 4 mM EDTA and 
2 mM dithiothreitol in 0.1 M phosphate bufTe.r (pH 7.4). The reaction 
mixture was incubated for 20 min at 37”C, and the fluorescence of the 
MCA released was determined according to [lo]. This cysteine pro- 
teinase was purified approximately 25 times from the original extract, 
using a modification of the method reported by Arvidson et al. [l I]. 
The inhibition of SAVI cysteine proteinase by P-cystatin a or 
comified envelope was assayed by incubating P-cystatin a with SAVS 
cysteine proteinase for 10 min at 37’C and by incubating the purified 
comified envelope suspension with 4% Brij-35 for 10 min at 37”C, 
respectively. 
2.5. Irnmunostaining of P-cystatin a in sphingosine-treated model skin 
Treatment with sphingosine, a natural inhibitor of protein ltinase C, 
leads to a remarkable decrease in the amount of P-cystatin a in kera- 
tohyalin granules [2], Sphingosine was applied to newborn rat skin for 
3 days and the skin was then stained with anti-Pcystatin a PoAb. 
DMSO was used as the control. The skin was embedded in Tissue Tek 
OCT compound and cryostat sections that had been tixed in cold 
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Fig. 1. Morphological demonstration of P-cystatin a contents in various model skins using anti-Pcystatin a PoAb. (A,D,G) Untreated control skin; 
(B,E,H) DMSO-treated skin; (C,F,I) sphingosine-treated skin; (A,B,C) hematoxylin-eosin staining; @,E,F) immunofluorescent staining of P-cystatin 
a contents using anti-P-cystatin a PoAb; (G,H,I) immunoelectron microscopic detection of P-cystain a contents using anti-Pcystatin a PoAb. 
Arrowheads in D, E, G and H indicate the specific reaction of anti-P-cystatin a PoAb. 
ethanol for 4 min were prepared. After treatment with sphingosine or 
DMSO, the comified envelope was subjected to heat and SDS treat- 
ment and reacted with anti-P-cystatin a PoAb, then with anti-rabbit 
IgG goat IgG labelled with gold particles. T’he specimens were embed- 
ded in Epon and ultrathin sections were prepared for electron micro- 
scopic observation. Papain inhibition of comified envelope treated with 
sphingosine or DMSO was compared. 
2.6. Suppression ofSAV8 colony formation by P-cystatin a in the model 
skin 
The experimental designs are illustrated in the explanatory footnote 
in Fig. 3. Namely, a bacterial suspension diluted with 0.9% NaCl was 
incubated with or without P-cystatin a. Filter papers (2 cm in diameter) 
were soaked in an aliquot of these solutions (0.2 ml) and were placed 
on the back skin of newborn rats for 15 h at 15°C. Bacterial suspension 
that had been preincubated with P-cystatin a was inoculated on the 
sphingosine-treated skin shown in Fig. 3a. As a control, bacterial sus- 
pension that had not been pretreated with P-cyst&in a was also inocu- 
lated on the sphingosine-treated skin, the DMSO-treated skin, and the 
non-treated skin, as shown in Fig. 3b, c and d, respectively. After the 
incubation of these inoculated skins for 15 h at lYC, the number of 
SAVI colonies on the respective skin specimens was determined by the 
stamp agar method. 
3. Results 
The activity of SAV8 cysteine proteinase was inhibited 
by P-cystatin a and by the comified envelope; P-cystatin a 
was solubilized in phosphate buffer, the cornified envelope was 
used as a suspension. The inhibitory activity of the cornified 
” 
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Amount of cornified envelope (pg) 
Fig. 2. Inhibition of papain by comified envelope purified from skins 
treated with DMSO or sphingosine. Open circles and closed circles 
indicate comified envelope purified from skins treated with DMSO or 
sphingosine, respectively. 
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A filter paper soaked with S. aureus V8 solution was placed on the back skin of newborn rats 
for 15 hours at 15-C 
The number of colonies was counted by the stamp agar method. 
Fig. 3. Comparison of SAVS colony formation on the surfaces of sphingosine-treated or untreated skin. (a) Preincubated SAV8 with Pcystatin a; 
@,c,d) preincubated SAVS without Pcystatin a; (a,b) sphingosine treated skin (low P-cystatin a level); (c) DMSO treated skin (high P-cystatin a
level); (d) normal skin without any treatment (high P-cystatin a level). The procedure described above shows the experimental design for suppression 
of SAVS colony formation by P-cystatin a in the wr&fied envelope. 
envelope appeared to be weaker than that of P-cystatin a. Since 
the comified envelope is insoluble, the inhibitory reaction was 
carried out with a suspension. Immunofluorescent and immu- 
noelectron microscopic studies showed a marked decrease in 
P-cystatin a content in the cornified envelope treated with 
sphingosine, as shown in Fig. 1. The amount of P-cystatin a in 
the DMSO-treated and untreated control skins was much 
greater than that in the sphingosine-treated skin. The inhibitory 
activity of comified envelope proteins against papain was com- 
pared; the protein prepared from sphingosine-treated skin 
showed much weaker inhibition than that shown by the protein 
prepared from DMSO-treated skin as shown in Fig. 2. To test 
the bacteriostatic effects of P-cystatin a, the SAV8 suspension 
was inoculated on the sphingosine-treated model skin, which 
served as a solid medium. The number of SAV8 colonies on the 
sphingosine-treated model skin was much greater than the 
numbers on the skin treated with DMSO, and an untreated skin 
(Fig. 3). There were significant differences among the 4 groups 
in the numbers of colonies on the stamps, as shown in Fig. 
3a,b,c,d. However, when SAV8 was preincubated with P-cys- 
tatin a, colony formation was markedly suppressed, to the 
normal levels, as a of Figs. 3 and 4. There were significant 
differences in colony formation between the sphingosine- 
treated model skin as shown in b of Figs. 3 and 4 and the 
control skins as shown in c and d of Figs. 3 and 4. 
4. I3i!xxdon 
We found here that both the comilied envelope and P-cys- 
tatin a inhibited the activity of SAVI cysteine proteinase. As 
we have reported previously, the comified envelope seems to 
be formed by the conjugation of P-cystatin a, mediated by 
epidermal transglutaminase with a suitable glutamine-rich pro- 
tein [12], such as loricrin [13], involucrin [14], or fhaggrin [15], 
in the stratum comeum. Since P-cystatin a is a lysine-rich pro- 
tein, it is a good substrate for epidermal transglutaminase. 
P-cystatin a is a protein component of the comified envelope 
[4]. It is therefore possible that the inhibitory function of the 
comified envelope was due to P-cystatin a. We have also found 
that the inhibitory function of the comified envelope against 
cathepsin L was heat-stable (data not shown). It is interesting 
to note that free P-cystatin a inhibited the activity of cathepsins 
B, H, and L [3], but that the conjugated form of P-cystatin a 
did not inhibit against cathepsin B [16]. The biological signifi- 
cance and chemical mechanisms underlying this difference are 
not yet known; however, these features may be related to the 
fact that the most bacterial cysteine proteinases are of the 
cathepsin L type (papain type). In this experiment, we devel- 
oped a model skin system in which P-cystatin a was decreased 
by sphingosine treatment [4]. Colony formation was increased 
in sphingosine-treated model skin and was suppressed by the 
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Fig. 4. Quantitative illustration of the SAV8 colony formations on 
various experimental skins. Theexplanations ofcolumn a, b, c or d are 
described inFig. 3. *No sign&ant di!Terence; **p < 0.05; ***p < 0.01. 
The experiments were performed 4 times. 
addition of P-cystatin a, indicating that P-cystatin a in the 
cornified envelope of the skin may act as a barrier against some 
bacteria that contain cysteine proteinases. Sphingosine and Hl 
histone in the epidermis have been reported to have antimicro- 
bial and antifungal activities [17,18]. However, proteinase in- 
hibitors have also been reported to have antiviral, antimicro- 
bial, and antifungal activities [5-7,19,20]. Moreover, it is well 
known that Staphylococcus aureus is increased on the skin sur- 
face of the lesions of atopic dermatitis. Further, we have found, 
using immunohistochemical techniques, that the immunohisto- 
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chemical reactivity of cystatin A was decreased in the lesions 
of atopic dermatitis (unpublished data). Our findings indicated 
that the P-cystatin a contained in the coded envelope inhib- 
ited bacterial cysteine proteinases; thus, it would appear that 
P-cyst&in a may suppress the growth of bacteria. 
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